There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.

Described herein is the use of a methylated/sulfated hyaluronan, sulfated hyaluronan, or the pharmaceutically acceptable salt or ester thereof for the treatment of chronic rhinosinusitis.

Described herein is the use of a methylated/sulfated hyaluronan, sulfated hyaluronan, or the pharmaceutically acceptable salt or ester thereof for the treatment of chronic rhinosinusitis.

A surgical device for assisting in the placement of a prosthetic implant. One or more sheets of polymer are in the form of a conical frustum such that a proximal end is sealed and a distal end is open, with an elongated slit extending from the distal end toward the proximal end. A single opening is formed by the distal opening and the elongated slit with a set of inter-lockable fastener elements disposed along opposing sides and configured to seal the elongated slit such that the distal end remains open to allow for egress of the prosthetic implant for placement into a surgical pocket. A lubricious coating is applied to the interior cavity of the frustum in addition to one or more surface active coatings. Movement of the prosthetic implant across the one or more surface active coatings causes the coatings to provide one or more offered benefits.

A surgical device for assisting in the placement of a prosthetic implant. One or more sheets of polymer are in the form of a conical frustum such that a proximal end is sealed and a distal end is open, with an elongated slit extending from the distal end toward the proximal end. A single opening is formed by the distal opening and the elongated slit with a set of inter-lockable fastener elements disposed along opposing sides and configured to seal the elongated slit such that the distal end remains open to allow for egress of the prosthetic implant for placement into a surgical pocket. A lubricious coating is applied to the interior cavity of the frustum in addition to one or more surface active coatings. Movement of the prosthetic implant across the one or more surface active coatings causes the coatings to provide one or more offered benefits.

Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.

Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.

The present invention provides compositions comprised of oxidized cellulose (OC) and glycerol, with the ratio of glycerol to OC being at least about 0.5:1 w/w glycerol:OC and/or with the viscosity of the composition being at least 10% higher than that of the glycerol and lower than about 2.610.sup.9 cP, with the total water content being less than about 8% w/w. Further provided is adhesion prevention powder comprised of OC having a carboxyl content of equal to below 18% characterized by high adhesion prevention potency. Uses of the compositions as hemostats or as adhesion prevention material, and methods for the preparation thereof are further provided herein.

The present invention provides compositions comprised of oxidized cellulose (OC) and glycerol, with the ratio of glycerol to OC being at least about 0.5:1 w/w glycerol:OC and/or with the viscosity of the composition being at least 10% higher than that of the glycerol and lower than about 2.610.sup.9 cP, with the total water content being less than about 8% w/w. Further provided is adhesion prevention powder comprised of OC having a carboxyl content of equal to below 18% characterized by high adhesion prevention potency. Uses of the compositions as hemostats or as adhesion prevention material, and methods for the preparation thereof are further provided herein.

The present invention provides pentosan polysulfate having a weight average molecular weight of 5000 or less and a content of acetyl groups of 0% to 2.0% by mass, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. The pentosan polysulfate of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof exhibits an anti-Xa activity and an anti-Xa/anti-IIa activity ratio, which are suitable for practical use, and is useful as a pharmaceutical composition such as an anticoagulant.